{
    "Rank": 515,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT01958112",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "13-334"
                },
                "Organization": {
                    "OrgFullName": "Dana-Farber Cancer Institute",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "GSK1120212+GSK2141795 for Cervical Cancer",
                "OfficialTitle": "A Single Arm, Single Stage Phase II Trial of GSK1120212 and GSK2141795 in Persistent or Recurrent Cervical Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "May 2019",
                "OverallStatus": "Terminated",
                "WhyStopped": "Drug supply",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "October 2013"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "November 2017",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "November 2017",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "October 4, 2013",
                "StudyFirstSubmitQCDate": "October 4, 2013",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "October 8, 2013",
                    "StudyFirstPostDateType": "Estimate"
                },
                "ResultsFirstSubmitDate": "December 11, 2018",
                "ResultsFirstSubmitQCDate": "December 11, 2018",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "January 2, 2019",
                    "ResultsFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "May 8, 2019",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "May 31, 2019",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Ursula A. Matulonis, MD",
                    "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
                    "ResponsiblePartyInvestigatorAffiliation": "Dana-Farber Cancer Institute"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Dana-Farber Cancer Institute",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "Novartis",
                            "CollaboratorClass": "INDUSTRY"
                        },
                        {
                            "CollaboratorName": "National Comprehensive Cancer Network",
                            "CollaboratorClass": "NETWORK"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "This research study is evaluating the combination of two drugs called GSK1120212 (trametinib) and GSK2141795 as a possible treatment for recurrent or persistent cervical cancer. Trametinib and GSK2141795 are drugs that may stop cancer cells from growing. Trametinib is a MEK inhibitor - it blocks a protein called MEK that is commonly overactive in tumor cells. GSK2141795 is an AKT inhibitor which blocks a pathway in cancer cells that is commonly overactive in tumor cells called the PI3kinase pathway. In this research study, the investigator is looking to see whether the combination of Trametinib and GSK2141795 is useful in treating recurrent and persistent cervical cancer.\n\nAdditionally, the investigator is looking to see if participants whose tumors contain a particular genetic make-up will have better response to combination trametinib and GSK2141795. Participants' tumors will be tested for mutations in genes which could make some cancers more susceptible to trametinib and GSK2141795.",
                "DetailedDescription": "Before the research starts (screening): The participant will be asked to undergo some screening tests or procedures to find out if they can be in the research study. Many of these tests and procedures are likely to be part of regular cancer care and may be done even if it turns out that the participant does not take part in the research study. If the participant has had some of these tests or procedures recently, they may or may not have to be repeated.\n\nA medical history, which includes questions about the participant's health, current medications, and any allergies.\nPhysical exam, including height and weight\nAn eye exam, by an eye specialist\nPerformance status, the investigator will ask the participant questions about how they are able to carry on with your usual activities.\nVital signs, including blood pressure, pulse, body temperature and respiratory rate\nAn assessment of the participant's tumor by CT (Computerized Tomography) scan or MRI (Magnetic Resonance Imaging), of their chest, stomach area, and pelvis.\nBlood tests (approximately 2-3 tablespoons) including hematology, chemistry, liver function, kidney function, blood sugar levels, blood clotting levels\nElectrocardiogram (EKG), a test to check the participant's heart's rhythm\nEchocardiogram (ECHO), a test to check the participant's heart's structure and function.\nSerum pregnancy test if the participant are capable of becoming pregnant\n\nIf the results of the above tests show that the participant is eligible to participate in the research study, the participant will begin the study treatment. If the participant does not meet the eligibility criteria, the participant will not be able to participate in this research study.\n\nIf these tests show that the participant is eligible to participate in the research study, the participant will begin the study treatment. If the participant does not meet the eligibility criteria, the participant will not be able to participate in this research study.\n\nAdditional research procedures to be performed at the time of screening:\n\n- Archival tumor testing: During this study, additional tests will be performed on a sample of the participant's original tumor that has been stored in your institution's tissue banks. These tests will be performed on tumor tissue samples from previous biopsies or surgeries for the participant's cancer. The research done on these samples will involve looking at DNA and proteins in the participant's cancer to see if researchers can learn more about the participant's type of cancer and understand how trametinib and GSK2141795 might work on their tumor. Testing of this sample will not require the participant to undergo any additional procedures.\n\nTISSUE COLLECTIONS/OWNERSHIP: Participation in this protocol involves providing specimen(s) of the participant's tissue. Please know that if the investigator leaves the institution, the research and the tissue might remain at the DF/HCC or might be transferred to another institution.\n\nAdditional Blood tests: Approximately 2 tablespoons of blood will be collected for research testing. This testing will involve looking at DNA and proteins in the participant's blood to compare them with those seen in their cancer. This will be drawn before the participant begin taking the study drug. These research sample collections are a required part of this research study. If the participant does not wish to undergo these procedures, the participant may not participate in this research study.\nOptional pre and post tumor biopsies: Before the participant begin receiving the study drug, your doctor will arrange for a procedure where your tumor will be biopsied. Your entire tumor or part of your tumor might be removed (excisional biopsy) or a small sample of the tumor might be removed using a needle (needle biopsy, fine needle aspirate) with guidance under radiographic studies. This will also occur before the participant begins treatment and between 2-4 weeks after treatment has started.\n\nAfter the screening procedures confirm that the participant is eligible to participate in the research study:\n\nStudy Drugs:\n\nIf the participant decides to take part in this research study, the participant will be given a study drug diary for each treatment cycle. The participant will be asked to complete a drug diary to record when they took each dose or to give a reason if the participant did not take the study drugs. At the end of each cycle, the participant should return the pill bottles and all of the remaining pills prior to starting the next cycle. The participant will receive a new set of pills and new diary if the participant is to continue the next cycle.\n\nClinical Exams: During all cycles the participant will have a physical exam, and will be asked questions about their general health and specific questions about any problems that they might having and any medications the participant may be taking.\n\nThe participant can expect the following while they are a participant on this study.\n\nAt the beginning of each cycle (one cycle equals 28 days):\n\nRecording of any health problems, including side effects of the study drugs\nList of medications taken since the last visit\nPhysical examination (including measurement of vital signs, such as blood pressure, breathing rate, heart rate, temperature and weight)\nEvaluation of the participant's performance status (the ability to carry on daily activities)\nBlood samples (approximately 2-3 tablespoons of blood will be taken) to evaluate the participant's blood counts, electrolytes, liver function, kidney function and blood sugar levels.\nEKG, a test to check the participant's heart's rhythm. This will be performed at the start on each cycle.\n\nOnce a week during the first cycle:\n\nThe participant will be called by a member of the study team to record any health problems, including side effects from the study drugs and any changes in medications.\nBlood samples (approximately 1 teaspoon of blood will be taken) to evaluate their blood sugar levels. This can be done at a lab close to home. If the participant's doctor thinks that their blood sugars need further monitoring, the participant may have continued blood samples drawn to check their blood sugar weekly or daily past the first cycle.\n\nEvery 2 cycles:\n\nBlood samples (approximately 1 teaspoon of blood will be taken) to evaluate the participant's HgbA1C, a test that evaluates their blood sugar levels over a period of time. This can be done at a lab close to home.\nCT scan or MRI of your chest, stomach area, and pelvis to see if the participant's cancer is increasing, decreasing, or staying the same size. If the cancer is decreasing, the participant's doctor may schedule the participant for another CT scan in about one month to check it again.\nECHO, a test to check the participant's heart's structure and function\n\nAt the end of the study:\n\nRecording of any health problems, including any side effects from the study drugs.\nList of medications taken since the last visit\nPhysical examination (including measurement of the participant's vital signs, such as blood pressure, breathing rate, heart rate, temperature, and weight.)\nEvaluation of the participant's performance status (their ability to carry on daily activities).\nBlood samples (approximately 2-3 tablespoons of blood will be taken) to evaluate the participant's blood counts, electrolytes, liver function, kidney function, blood sugar level, and HgbA1C.\n\nAfter the final dose of the study drug:\n\nThe investigator would like to keep track of the participant's medical condition for up to 3 years after the participant completes the study. The investigator would like to do this by calling the participant on the telephone or seeing the participant in clinic for evaluation of their status, disease and current therapy. Keeping in touch with the participant and checking their condition routinely helps us look at the long-term effects of the research study."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Cervical Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Cervical Cancer",
                        "Cervical",
                        "Cervix"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "14",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "GSK1120212 (trametinib) and GSK2141795",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: GSK1120212 (trametinib)",
                                    "Drug: GSK2141795"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "GSK1120212 (trametinib)",
                            "InterventionDescription": "Trametinib dose is 1.5 mg orally once per day",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "GSK1120212 (trametinib) and GSK2141795"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Trametinib"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "GSK2141795",
                            "InterventionDescription": "The dose of GSK2141795 is 50 mg orally once per day",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "GSK1120212 (trametinib) and GSK2141795"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Response Rate for the Combination of GSK1120212 (Trametinib) and GSK2141795 in Patients With Recurrent or Persistent Cervical Cancer.",
                            "PrimaryOutcomeDescription": "Response rate will be assessed by RECIST version 1.1.",
                            "PrimaryOutcomeTimeFrame": "2 Years"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Duration of Progression-free (PFS)",
                            "SecondaryOutcomeDescription": "The duration of progression-free (PFS) following initiation of therapy with GSK1120212 (trametinib) and GSK2141795 will be measured.",
                            "SecondaryOutcomeTimeFrame": "2 Years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Toxicity of GSK1120212 (Trametinib) and GSK2141795 as Measured by the Number of Participants With Adverse Events",
                            "SecondaryOutcomeDescription": "Toxicity was assessed for this combination by version 4.0 of the NCI Common Terminology Criteria for Adverse Events (CTCAE) in this cohort of patients. Toxicities reported were deemed related to study treatment.",
                            "SecondaryOutcomeTimeFrame": "2 Years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Mutation and Co-mutation Rates of Genes in the PI3K and RAS ERK Signaling Pathways in Recurrent Cervical Cancer Using High Throughput Targeted Mutational Analysis on Participant Tumor Samples.",
                            "SecondaryOutcomeDescription": "The mutation and co-mutation rates of genes in the PI3K and RAS ERK signaling pathways in recurrent cervical cancer will be interrogated using high throughput targeted mutational analysis on participant tumor samples.",
                            "SecondaryOutcomeTimeFrame": "2 Years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Overall Survival",
                            "SecondaryOutcomeDescription": "Overall survival will be determined for subjects on this study",
                            "SecondaryOutcomeTimeFrame": "2 years"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nRecurrent or metastatic cervical cancer of any histology\nMeasurable disease by RECIST 1.1.\nPrior Therapy:\nAt least one prior chemotherapy regimen for management of cervical cancer. Radiation-sensitizing chemotherapy will not be counted as a systemic chemotherapy regimen\nPatients can have received one additional regimen for treatment\nNo prior receipt of PI3K or RAS-ERK pathway inhibitors\nAge \u2265 18 years\nLife expectancy > 3 mos\nECOG performance status \u2264 2\nParticipants must have normal organ function as defined below:\nAbsolute Neutrophil Count (ANC)\u2265 1,500/mcL\nPlatelets \u2265 100,000/mcL\nHemoglobin > 9.0/dL\nAST (SGOT) and ALT (SGPT) \u2264 2.5 \u00d7 institutional ULN\nTotal Bilirubin within normal institutional limits\nAlbumin \u2265 2.5 g/dL\nCreatinine \u2264 upper limit of institutional normal or creatinine clearance \u2265 50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal or \u2265 50 mL/min 24-hour creatinine clearance\nNormal LVEF\nNormal fasting Blood Glucose\nAvailability of a formalin fixed paraffin embedded (FFPE) block of cancer tissue\nNormal blood pressure (systolic < 140 mmHg and diastolic < 90 mmHg)\nWomen of childbearing potential must agree to use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation\nToxicities of prior therapy (excepting alopecia) should be resolved to \u2264 grade 1\nAbility to tolerate oral medications and no malabsorption\nAbility to sign an informed consent\n\nExclusion Criteria:\n\nNo previous chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C,) or radiation therapy within 2 weeks prior to entering the study\nNo use of investigational agents nor have participated in an investigational trial within the past 4 weeks (or five half-lives whichever is shorter; with a minimum of 14 days from the last dose).\nPresence of active GI disease that could affect GI absorption or predispose a subject to GI ulceration.\nEvidence of mucosal of internal bleeding\nMajor surgery within the last 4 weeks\nNo Type 1 diabetes; however, patients with Type 2 diabetes are eligible if diagnosed \u2265 6 months prior to enrollment and if hemoglobin A1C (HbA1C) \u2264 8% at screening.\nSymptomatic or unstable brain metastases or asymptomatic and untreated but > 1 cm in the longest dimension\nSymptomatic or untreated leptomeningeal or spinal cord compression.\nIndividuals with a history of a different malignancy are ineligible except for the following circumstances: the following cancers are eligible if diagnosed and treated within the past 3 years: breast cancer in situ and basal cell or squamous cell carcinoma of the skin, stage I colon carcinoma confined to a polyp.\nAny serious and/or unstable pre-existing medical disorders\nKnown infection with HIV, Hepatitis B Virus, or Hepatitis C Virus\nChronic use of drugs that are strong inhibitors or inducers of p450 CYP3A4\nknown immediate or delayed hypersensitivity reaction or idiosyncrasy to study drugs\nHistory of interstitial lung disease or pneumonitis.\nPresence of cardiac metastases\nSubject with intra-cardiac defibrillators or pacemaker.\nHistory or current evidence / risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)\nHistory of RVO or CSR, or predisposing factors to RVO or CSR\nVisible retinal pathology as assessed by ophthalmic exam\nHistory or evidence of cardiovascular risk including any of the following\nQTcF\u2265 480 msec ( \u2265 500 msec for subject with bundle branch block)\nHistory or evidence of current clinically significant uncontrolled arrhythmias. (Exception: controlled atrial fibrillation for >30 days prior to randomization)\nHistory of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months of study entry.\nClass II or higher congestive heart failure.",
                "HealthyVolunteers": "No",
                "Gender": "Female",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Ursula A. Matulonis, MD",
                            "OverallOfficialAffiliation": "Dana-Farber Cancer Institute",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Dana-Farber Cancer Institute",
                            "LocationCity": "Boston",
                            "LocationState": "Massachusetts",
                            "LocationZip": "02215",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "No"
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "GSK1120212 (Trametinib) and GSK2141795",
                            "FlowGroupDescription": "GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles\n\nGSK1120212 (trametinib): Trametinib dose is 1.5 mg orally once per day\n\nGSK2141795: The dose of GSK2141795 is 50 mg orally once per day"
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Overall Study",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "GSK1120212 (Trametinib) and GSK2141795",
                            "BaselineGroupDescription": "GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles\n\nGSK1120212 (trametinib): Trametinib dose is 1.5 mg orally once per day\n\nGSK2141795: The dose of GSK2141795 is 50 mg orally once per day"
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "14"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Categorical",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "<=18 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Between 18 and 65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "9"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": ">=65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "5"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "14"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Race (NIH/OMB)",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Asian",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Black or African American",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "White",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "14"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "More than one race",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Unknown or Not Reported",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Region of Enrollment",
                            "BaselineMeasureParamType": "Number",
                            "BaselineMeasureUnitOfMeasure": "participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineClassTitle": "United States",
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "14"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Response Rate for the Combination of GSK1120212 (Trametinib) and GSK2141795 in Patients With Recurrent or Persistent Cervical Cancer.",
                            "OutcomeMeasureDescription": "Response rate will be assessed by RECIST version 1.1.",
                            "OutcomeMeasurePopulationDescription": "Response rate assessed by RECIST version 1.1.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "2 Years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "GSK1120212 (Trametinib) and GSK2141795",
                                        "OutcomeGroupDescription": "GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles\n\nGSK1120212 (trametinib): Trametinib dose is 1.5 mg orally once per day\n\nGSK2141795: The dose of GSK2141795 is 50 mg orally once per day"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "14"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeCategoryTitle": "Complete Response",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "Partial Response",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "Stable Disease",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "8"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "Unevaluable",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "Progressive Disease",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "3"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Duration of Progression-free (PFS)",
                            "OutcomeMeasureDescription": "The duration of progression-free (PFS) following initiation of therapy with GSK1120212 (trametinib) and GSK2141795 will be measured.",
                            "OutcomeMeasurePopulationDescription": "PFS events were determined by RECIST 1.1, clinical progression and death.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Median",
                            "OutcomeMeasureDispersionType": "95% Confidence Interval",
                            "OutcomeMeasureUnitOfMeasure": "months",
                            "OutcomeMeasureTimeFrame": "2 Years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "GSK1120212 (Trametinib) and GSK2141795",
                                        "OutcomeGroupDescription": "GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles\n\nGSK1120212 (trametinib): Trametinib dose is 1.5 mg orally once per day\n\nGSK2141795: The dose of GSK2141795 is 50 mg orally once per day"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "11"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "3.7",
                                                                "OutcomeMeasurementLowerLimit": "1.9",
                                                                "OutcomeMeasurementUpperLimit": "NA",
                                                                "OutcomeMeasurementComment": "Study was stopped prematurely, insufficient number of participants with events."
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Toxicity of GSK1120212 (Trametinib) and GSK2141795 as Measured by the Number of Participants With Adverse Events",
                            "OutcomeMeasureDescription": "Toxicity was assessed for this combination by version 4.0 of the NCI Common Terminology Criteria for Adverse Events (CTCAE) in this cohort of patients. Toxicities reported were deemed related to study treatment.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "2 Years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "GSK1120212 (Trametinib) and GSK2141795",
                                        "OutcomeGroupDescription": "GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles\n\nGSK1120212 (trametinib): Trametinib dose is 1.5 mg orally once per day\n\nGSK2141795: The dose of GSK2141795 is 50 mg orally once per day"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "14"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "14"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Mutation and Co-mutation Rates of Genes in the PI3K and RAS ERK Signaling Pathways in Recurrent Cervical Cancer Using High Throughput Targeted Mutational Analysis on Participant Tumor Samples.",
                            "OutcomeMeasureDescription": "The mutation and co-mutation rates of genes in the PI3K and RAS ERK signaling pathways in recurrent cervical cancer will be interrogated using high throughput targeted mutational analysis on participant tumor samples.",
                            "OutcomeMeasurePopulationDescription": "Observed mutations and amplifications in genes related to PI3K or RAS signaling in the 13 patients with tissue available for testing. One patient did not have archival tissue available for testing, five patients did not have detected alterations.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "2 Years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "GSK1120212 (Trametinib) and GSK2141795",
                                        "OutcomeGroupDescription": "GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles\n\nGSK1120212 (trametinib): Trametinib dose is 1.5 mg orally once per day\n\nGSK2141795: The dose of GSK2141795 is 50 mg orally once per day"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "13"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeClassTitle": "Adenocarcinoma",
                                        "OutcomeClassDenomList": {
                                            "OutcomeClassDenom": [
                                                {
                                                    "OutcomeClassDenomUnits": "Participants",
                                                    "OutcomeClassDenomCountList": {
                                                        "OutcomeClassDenomCount": [
                                                            {
                                                                "OutcomeClassDenomCountGroupId": "OG000",
                                                                "OutcomeClassDenomCountValue": "5"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeCategoryTitle": "PIK3CA mutation",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "PIK3CA amplification",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "KRAS abberation",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Squamous Cell Carcinoma",
                                        "OutcomeClassDenomList": {
                                            "OutcomeClassDenom": [
                                                {
                                                    "OutcomeClassDenomUnits": "Participants",
                                                    "OutcomeClassDenomCountList": {
                                                        "OutcomeClassDenomCount": [
                                                            {
                                                                "OutcomeClassDenomCountGroupId": "OG000",
                                                                "OutcomeClassDenomCountValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeCategoryTitle": "PIK3CA mutation",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "PIK3CA amplification",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "KRAS abberation",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Mucinous",
                                        "OutcomeClassDenomList": {
                                            "OutcomeClassDenom": [
                                                {
                                                    "OutcomeClassDenomUnits": "Participants",
                                                    "OutcomeClassDenomCountList": {
                                                        "OutcomeClassDenomCount": [
                                                            {
                                                                "OutcomeClassDenomCountGroupId": "OG000",
                                                                "OutcomeClassDenomCountValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeCategoryTitle": "PIK3CA mutation",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "PIK3CA amplification",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "KRAS abberation",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Overall Survival",
                            "OutcomeMeasureDescription": "Overall survival will be determined for subjects on this study",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Median",
                            "OutcomeMeasureDispersionType": "95% Confidence Interval",
                            "OutcomeMeasureUnitOfMeasure": "months",
                            "OutcomeMeasureTimeFrame": "2 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "GSK1120212 (Trametinib) and GSK2141795",
                                        "OutcomeGroupDescription": "GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles\n\nGSK1120212 (trametinib): Trametinib dose is 1.5 mg orally once per day\n\nGSK2141795: The dose of GSK2141795 is 50 mg orally once per day"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "11"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "14.8",
                                                                "OutcomeMeasurementLowerLimit": "6.7",
                                                                "OutcomeMeasurementUpperLimit": "NA",
                                                                "OutcomeMeasurementComment": "Study stopped prematurely, insufficient number of participants with events."
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "5",
                "EventsTimeFrame": "2 years, 2 months",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "GSK1120212 (Trametinib) and GSK2141795",
                            "EventGroupDescription": "GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles\n\nGSK1120212 (trametinib): Trametinib dose is 1.5 mg orally once per day\n\nGSK2141795: The dose of GSK2141795 is 50 mg orally once per day",
                            "EventGroupDeathsNumAffected": "8",
                            "EventGroupDeathsNumAtRisk": "14",
                            "EventGroupSeriousNumAffected": "3",
                            "EventGroupSeriousNumAtRisk": "14",
                            "EventGroupOtherNumAffected": "1",
                            "EventGroupOtherNumAtRisk": "14"
                        }
                    ]
                },
                "SeriousEventList": {
                    "SeriousEvent": [
                        {
                            "SeriousEventTerm": "Thromboembolic event",
                            "SeriousEventOrganSystem": "Blood and lymphatic system disorders",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "2",
                                        "SeriousEventStatsNumAffected": "2",
                                        "SeriousEventStatsNumAtRisk": "14"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "colonic perforation",
                            "SeriousEventOrganSystem": "Gastrointestinal disorders",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "14"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Hypophosphatemia",
                            "SeriousEventOrganSystem": "Investigations",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "14"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Retinal pigment epithelial detachment",
                            "SeriousEventOrganSystem": "Eye disorders",
                            "SeriousEventAssessmentType": "Non-systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "14"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "OtherEventList": {
                    "OtherEvent": [
                        {
                            "OtherEventTerm": "rash acneiform",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "14"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "No",
                    "AgreementRestrictionType": "LTE60",
                    "AgreementRestrictiveAgreement": "Yes"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "Dr. Ursula Matulonis",
                    "PointOfContactOrganization": "Dana-Farber Cancer Institute",
                    "PointOfContactEMail": "ursula_matulonis@dfci.harvard.edu",
                    "PointOfContactPhone": "617-632-2334"
                }
            }
        },
        "DocumentSection": {
            "LargeDocumentModule": {
                "LargeDocList": {
                    "LargeDoc": [
                        {
                            "LargeDocTypeAbbrev": "Prot_SAP",
                            "LargeDocHasProtocol": "Yes",
                            "LargeDocHasSAP": "Yes",
                            "LargeDocHasICF": "No",
                            "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
                            "LargeDocDate": "July 11, 2017",
                            "LargeDocUploadDate": "12/07/2018 11:03",
                            "LargeDocFilename": "Prot_SAP_000.pdf"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000002583",
                            "ConditionMeshTerm": "Uterine Cervical Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000014594",
                            "ConditionAncestorTerm": "Uterine Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000005833",
                            "ConditionAncestorTerm": "Genital Neoplasms, Female"
                        },
                        {
                            "ConditionAncestorId": "D000014565",
                            "ConditionAncestorTerm": "Urogenital Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000002577",
                            "ConditionAncestorTerm": "Uterine Cervical Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000014591",
                            "ConditionAncestorTerm": "Uterine Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005831",
                            "ConditionAncestorTerm": "Genital Diseases, Female"
                        },
                        {
                            "ConditionAncestorId": "D000052776",
                            "ConditionAncestorTerm": "Female Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005261",
                            "ConditionAncestorTerm": "Female Urogenital Diseases and Pregnancy Complications"
                        },
                        {
                            "ConditionAncestorId": "D000091642",
                            "ConditionAncestorTerm": "Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000091662",
                            "ConditionAncestorTerm": "Genital Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M14540",
                            "ConditionBrowseLeafName": "Recurrence",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M5520",
                            "ConditionBrowseLeafName": "Uterine Cervical Neoplasms",
                            "ConditionBrowseLeafAsFound": "Cervical Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M17032",
                            "ConditionBrowseLeafName": "Uterine Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8635",
                            "ConditionBrowseLeafName": "Genital Neoplasms, Female",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M17005",
                            "ConditionBrowseLeafName": "Urogenital Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M5515",
                            "ConditionBrowseLeafName": "Uterine Cervical Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M17029",
                            "ConditionBrowseLeafName": "Uterine Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8633",
                            "ConditionBrowseLeafName": "Genital Diseases, Female",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2877",
                            "ConditionBrowseLeafName": "Genital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2876",
                            "ConditionBrowseLeafName": "Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M26783",
                            "ConditionBrowseLeafName": "Female Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M13817",
                            "ConditionBrowseLeafName": "Pregnancy Complications",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8089",
                            "ConditionBrowseLeafName": "Female Urogenital Diseases and Pregnancy Complications",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BXS",
                            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "C000560077",
                            "InterventionMeshTerm": "Trametinib"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000047428",
                            "InterventionAncestorTerm": "Protein Kinase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M218428",
                            "InterventionBrowseLeafName": "Trametinib",
                            "InterventionBrowseLeafAsFound": "You",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M25510",
                            "InterventionBrowseLeafName": "Protein Kinase Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}